Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    CAR-TCR Global 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Multiple Myeloma

Targeting neoantigens in multiple myeloma with CAR T-cell 5:56
Targeting neoantigens in multiple myeloma with CAR T-cell
Angela Krackhard • 6 Apr 2022
Updates in cell and gene therapy approvals 1:27
Updates in cell and gene therapy approvals
Bruce Levine • 27 Jan 2022
Exciting advances in CAR-T and TCR research 2:49
Exciting advances in CAR-T and TCR research
David Gilham • 22 Feb 2021
Challenges of CAR T-cell therapy for AML: is CD38 the answer? 6:10
Challenges of CAR T-cell therapy for AML: is CD38 the answer?
Lei Yu • 3 Jun 2021
Improving education in cell therapy 1:33
Improving education in cell therapy
Emanuele Ostuni • 12 Apr 2021
The European cell & gene therapy landscape 1:27
The European cell & gene therapy landscape
Paige Bischoff • 17 Mar 2021
A non-gene edited approach to allogeneic CAR-T development 2:21
A non-gene edited approach to allogeneic CAR-T development
Filippo Petti • 6 Apr 2021
Investigating allogeneic iNKT cell therapy 8:28
Investigating allogeneic iNKT cell therapy
Marc van Dijk • 23 Feb 2021
CT053, anti-GPC3 CAR-T and targeting solid tumors 4:15
CT053, anti-GPC3 CAR-T and targeting solid tumors
Hong Ma • 19 Feb 2021
Myeloma Patients Europe: collaborating on projects to benefit the myeloma community 2:49
Myeloma Patients Europe: collaborating on projects to benefit the myeloma community
Ananda Plate • 11 Feb 2021
Novel strategies to optimize CAR T-cell therapy 4:31
Novel strategies to optimize CAR T-cell therapy
Arnon Nagler • 1 Feb 2021
CAR T-cells in myeloma: patients’ perspective 1:52
CAR T-cells in myeloma: patients’ perspective
Ananda Plate • 11 Feb 2021
The importance of partnering with patient organizations 3:48
The importance of partnering with patient organizations
Ananda Plate • 11 Feb 2021
Progression of CAR-T trials in China 2:19
Progression of CAR-T trials in China
Jianxiang Wang • 2 Feb 2021
CAR-T trials to watch in China 3:21
CAR-T trials to watch in China
Jianxiang Wang • 2 Feb 2021
CAR-T in myeloma: key players in the therapeutic landscape 4:32
CAR-T in myeloma: key players in the therapeutic landscape
Mohamad Mohty • 26 Jan 2021
  • 1
  • 2
  • Next
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy